Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 33.95M 24.19M 21M 19.66M 17.98M 2.3B 34.39M 230M 90.26M 1.15B 90.84M 88.87M 3.83B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 33.72M 24.03M 20.85M 19.53M 17.86M 2.29B 34.16M 228M 89.65M 1.14B 90.22M 88.26M 3.81B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 24.19M
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
+2.37%+5.63%+49.94%+41.02% 358B
+1.07%-0.06%+35.97%+40.81% 293B
+1.38%-4.78%+9.84%+10.49% 247B
-0.73%+4.44%+42.22%+66.41% 219B
+4.63%+0.55%-0.21%-43.52% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average +0.60%-1.90%+32.33%+51.53% 399.14B
Weighted average by Cap. +0.20%-0.83%+41.29%+78.39%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.4 0.03 0.03 1.32
Net income -1.71M -1.22M -1.06M -989K -904K -116M -1.73M -11.57M -4.54M -57.9M -4.57M -4.47M -193M -3.53M -2.52M -2.18M -2.05M -1.87M -240M -3.58M -23.93M -9.39M -120M -9.45M -9.25M -399M
Net Debt -113K -80.26K -69.65K -65.22K -59.66K -7.65M -114K -763K -299K -3.82M -301K -295K -12.71M -231K -164K -143K -134K -122K -15.65M -234K -1.56M -613K -7.82M -617K -603K -26.03M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise